Skip to main content
SpringerLink
Log in

Pioglitazone Lowers Blood Pressure in Hypertensive Patients with Type 2 Diabetes Mellitus

An Open, Multicentre, Observational Study

  • Short Communication
  • Published:
Clinical Drug Investigation Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

References

  1. Stamler J, Vaccaro O, Neaton JD, et al. Diabetes, other risk factors, and 12 year cardiovascular mortality for men screened in the multiple risk factor intervention trial. Diabetes Care 1993; 16: 434–44

    Article  PubMed  CAS  Google Scholar 

  2. Perneger TV, Brancati FL, Whelton PK, et al. End-stage renal disease attributable to diabetes mellitus. Ann Intern Med 1994; 121: 912–8

    PubMed  CAS  Google Scholar 

  3. United Kingdom Prospective Diabetes Study Group. UK Prospective Diabetes Study 23: risk factors for coronary artery disease in non-insulin dependent diabetes. BMJ 1998; 316: 823–8

    Article  Google Scholar 

  4. Hypertension in Diabetes Study Group. HDS 2: increased risk of cardio-vascular complications in hypertensive type 2 diabetic patients. J Hypertens 1993; 11: 319–25

    Article  Google Scholar 

  5. United Kingdom Prospective Diabetes Study Group. UK Prospective Diabetes Study X: urinary albumin excretion over 3 years in diet-treated type 2 (non-insulin-dependent) diabetic patients, and association with hypertension, hyperglycaemia and hypertriglyceridaemia. Diabetologia 1993; 36: 1021–9

    Article  Google Scholar 

  6. Nelson RG, Bennett PH, Beck GJ, et al. Development and progression of renal disease in Pima Indians with non-insulin-dependent diabetes mellitus. N Engl J Med 1996; 335: 1636–42

    Article  PubMed  CAS  Google Scholar 

  7. United Kingdom Prospective Diabetes Study Group. UK Prospective Diabetes Study 30: diabetic retinopathy at diagnosis of type 2 diabetes and associated risk factors. Arch Ophthalmol 1998; 116: 297–303

    Google Scholar 

  8. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703–13

    Article  Google Scholar 

  9. Ferranini E. Insulin resistance and blood pressure. In: Reaven G, Laws A, editors. Contemporary endocrinology: insulin resistance: the metabolic syndrome X. Totowa (NJ): Humana Press Inc., 1999: 281–308

    Google Scholar 

  10. Guidelines Subcommittee. 1999 World Health Organization-International Society of Hypertension. Guidelines for the management of hypertension. J Hypertens 1999; 17: 151–83

    Google Scholar 

  11. Haffner SM, Mykkanen L, Festa A, et al. Insulin-resistant pre-diabetic subjects have more atherogenic risk factors than insulin-sensitive pre-diabetic subjects: implications for preventing coronary heart disease during pre-diabetic state. Circulation 2000; 101: 975–80

    Article  PubMed  CAS  Google Scholar 

  12. Martens FMAC, Visseren FLJ, Lemay J, et al. Metabolic and additional vascular effects of thiazolidinediones. Drugs 2002; 62(10): 1463–80

    Article  PubMed  CAS  Google Scholar 

  13. Diamant M, Heine RJ. Thiazolidinediones in type II diabetes mellitus: current clinical evidence. Drugs 2003; 63(13): 1373–405

    Article  PubMed  CAS  Google Scholar 

  14. Gilling L, Suwattee P, DeSouza C, et al. Effects of the thiazolidinediones on cardiovascular risk factors. Am J Cardiovasc Drugs 2002; 2(3): 149–56

    Article  PubMed  CAS  Google Scholar 

  15. Füllen S, Schneider F, Haak E, et al. Effects of pioglitazone in non-diabetic patients with arterial hypertension: a double-blind, placebo-controlled study. J Clin Endocrinol Metab 2002; 87: 5503–6

    Article  Google Scholar 

  16. Gerber P, Lübben G, Heusler S, et al. Effects of pioglitazone on metabolic control and blood pressure: a randomised study in patients with type 2 diabetes mellitus. Curr Med Res Opin 2003; 19(6): 532–9

    Article  PubMed  CAS  Google Scholar 

  17. Göke B. Improved glycemic control and lipid profile in a randomized study of pioglitazone compared with acarbose in patients with type 2 diabetes mellitus. Treat Endocrinol 2002; 1: 329–36

    Article  PubMed  Google Scholar 

  18. US Department of Health and Human Services. The Seventh Report of the Joint National Committee on Prevention Detection Evaluation and Treatment of High Blood Pressure. NIH Publication No. 03-5233; 2003: 1–34

  19. Stolar MW, Chilton RJ. Type 2 diabetes, cardiovascular risk, and the link to insulin resistance. Clin Ther 2003; 25Suppl. B: B4–B31

    Article  PubMed  CAS  Google Scholar 

  20. Sutton MSJ, Rendell M, Dandona P, et al. A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes. Diabetes Care 2002; 25(11): 2058–64

    Article  CAS  Google Scholar 

  21. Bennett SMA, Agrawal A, Elashat H, et al. Rosiglitazone improves insulin sensitivity, glucose tolerance and ambulatory blood pressure in subjects with impaired glucose tolerance. Diabet Med 2004; 21: 415–22

    Article  PubMed  CAS  Google Scholar 

  22. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke and coronary artery disease. Part 1: prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335: 827–38

    Article  PubMed  CAS  Google Scholar 

  23. Sung BH, Izzo JL, Dandona P, et al. Vasodilatory effects of troglitazone improve blood pressure at rest and during mental stress in type 2 diabetes mellitus. Hypertension 1999; 34: 83–8

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

The study was supported by Takeda Pharma GmbH, Germany. The authors have no conflicts of interest that are directly relevant to the content of this article.

Author information

Authors and Affiliations

  1. Institut für Stoffwechselforschung, European RISC-Study Center, Heidelbergerstraβe 13, 60327, Frankfurt am Main, Germany

    Thomas Konrad, Georg Lübben & Christine Franzen

Authors
  1. Thomas Konrad
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Georg Lübben
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Christine Franzen
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Konrad, T., Lübben, G. & Franzen, C. Pioglitazone Lowers Blood Pressure in Hypertensive Patients with Type 2 Diabetes Mellitus. Clin. Drug Investig. 25, 337–340 (2005). https://doi.org/10.2165/00044011-200525050-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00044011-200525050-00006

Keywords

Search

Navigation